Similar articles

• Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.

  Agathocleous A, Rohatiner A, Rule S, Hunter H, Kerr JP, Neeson SM, Matthews J, Strauss S, Montoto S, Johnson P, Radford J, Lister A. Agathocleous A, et al. Br J Haematol. 2010 Nov;151(4):346-53. doi: 10.1111/j.1365-2141.2010.08340.x. Epub 2010 Sep 29. Br J Haematol. 2010. PMID: 20880120 Clinical Trial.
• Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.

  Furman RR, Martin P, Ruan J, Cheung YK, Vose JM, LaCasce AS, Elstrom R, Coleman M, Leonard JP. Furman RR, et al. Cancer. 2010 Dec 1;116(23):5432-9. doi: 10.1002/cncr.25509. Epub 2010 Jul 27. Cancer. 2010. PMID: 20665890 Clinical Trial.
• The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.

  Leleu X, Xie W, Bagshaw M, Banwait R, Leduc R, Roper N, Weller E, Ghobrial IM. Leleu X, et al. Clin Cancer Res. 2011 May 1;17(9):3013-8. doi: 10.1158/1078-0432.CCR-10-2954. Epub 2011 Mar 17. Clin Cancer Res. 2011. PMID: 21415221 Clinical Trial.
• Use of bortezomib in B-cell non-Hodgkin's lymphoma.

  Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Wang M, et al. Expert Rev Anticancer Ther. 2006 Jul;6(7):983-91. doi: 10.1586/14737140.6.7.983. Expert Rev Anticancer Ther. 2006. PMID: 16831071 Review.
• Fourth biannual report of the Cochrane Haematological Malignancies Group.

  Kober T, Hülsewede H, Bohlius J, Engert A. Kober T, et al. J Natl Cancer Inst. 2006 Apr 19;98(8):E1. doi: 10.1093/jnci/djj156. J Natl Cancer Inst. 2006. PMID: 16622111 Review. No abstract available.